Hydrocolloid Pimple Patch
Absorb, protect, and cover visible blemishes
Microdart Spot Patch
A two-step kit for the bump you can feel before you see it: prep with the Blemish Clearing Pad, then patch it with 16 dissolving microdarts.
Microdart Acne Patch
Coming soon: a two-step OTC acne treatment with dissolving microdarts and 2% salicylic acid, made for early-stage blemishes.
Hydrocolloid Pimple Patch
Absorb, protect, and cover visible blemishes
Microdart Spot Patch
A two-step kit for the bump you can feel before you see it: prep with the Blemish Clearing Pad, then patch it with 16 dissolving microdarts.
Microdart Acne Patch
Coming soon: a two-step OTC acne treatment with dissolving microdarts and 2% salicylic acid, made for early-stage blemishes.
Hydrocolloid Pimple Patch
Absorb, protect, and cover visible blemishes
Microdart Spot Patch
A two-step kit for the bump you can feel before you see it: prep with the Blemish Clearing Pad, then patch it with 16 dissolving microdarts.
Microdart Acne Patch
Coming soon: a two-step OTC acne treatment with dissolving microdarts and 2% salicylic acid, made for early-stage blemishes.
Press & Media
CLERIVY is a Korean skincare brand making hydrocolloid and microdart pimple patches for different spot stages. Operated by GUHADA Co., Ltd., the brand keeps its cosmetic patch formats separate from its planned OTC drug. On August 25, 2026, its Hydrocolloid Pimple Patch and Microdart Spot Patch became available to U.S. customers on Amazon.com. This official press room brings together verified product, testing, regulatory, launch, and media facts.
Company Announcement ·
On August 25, 2026, CLERIVY launched its Hydrocolloid Pimple Patch and Microdart Spot Patch on Amazon.com for U.S. customers. Both are cosmetic products designed for different spot stages. A separate OTC Microdart Acne Patch with 2% salicylic acid is planned for October 2026 and carries its own Drug Facts labeling.
Issued by CLERIVY, a brand operated by GUHADA Co., Ltd. · Distributed via PR Newswire.
These links document third-party distribution of CLERIVY's August 25, 2026 U.S. launch announcement. The U.S. and global pages are syndicated copies of the company announcement, not independent product reviews or editorial endorsements. The Korean-language outlets published articles about the launch.
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Korean-language launch article ·
구하다, 스킨케어 브랜드 ‘클레리비’ 미국 아마존 진출…OTC 패치는 10월 출시
Read CLERIVY launch coverage on Korea Daily (미주중앙일보) ↗Korean-language launch article ·
구하다, 자체 브랜드 트러블 패치 2종 미국 아마존 판매 개시
Read CLERIVY launch coverage on EToday (이투데이) ↗Korean-language launch article ·
‘검증된 성분’ 앞세웠다… 구하다, 자체 스킨케어 브랜드 미국 아마존 론칭
Read CLERIVY launch coverage on Fashionbiz (패션비즈) ↗Korean-language launch article ·
구하다, 美 트러블 케어 시장 공략…‘클레리비’ 아마존 론칭
Read CLERIVY launch coverage on MyDaily (마이데일리) ↗CLERIVY provides these direct third-party links for reference. Syndication indicates distribution, not an endorsement by the hosting platform.
If you are comparing Korean pimple patches, start with the stage of the spot and the product classification. Choose the cosmetic Microdart Spot Patch for an early bump you can feel before it surfaces. Choose the cosmetic Hydrocolloid Pimple Patch for a surfaced spot on healthy, intact skin that you want to cover. The Microdart Acne Patch is a separate OTC drug for acne with its own Drug Facts label and is scheduled for October 2026.
Early bump · Cosmetic · Available now
A cosmetic two-step kit for an early bump you can feel before it surfaces. Each 13.5 mm patch has 16 water-soluble microdarts and is used with the included Blemish Clearing Pad. The formula features 7% niacinamide, 3% tranexamic acid, and a vitamin C derivative. Available in 6-, 12-, and 18-patch kits.
Surfaced spot · Cosmetic · Available now
A cosmetic hydrocolloid patch for covering a surfaced spot on healthy, intact skin. Available in 10 mm and 12 mm sizes, with 30-, 72-, and 96-count boxes. Apply to clean, completely dry skin and follow the on-pack direction: wear for 4–8 hours, or until the patch turns opaque. Contains less than 0.5% salicylic acid for cosmetic purposes only.
OTC monograph drug · Scheduled for October 2026
A separate OTC monograph drug for acne with 2% salicylic acid as its sole active ingredient. Four- and eight-patch packs are planned for U.S. release in October 2026. Follow its Drug Facts label; do not apply the cosmetic-patch directions to this product.
Compare CLERIVY hydrocolloid and microdart pimple patches by spot stage →
The Hydrocolloid Pimple Patch and Microdart Spot Patch are cosmetics, not drugs. The Microdart Acne Patch is a separate OTC monograph drug. CLERIVY keeps these categories separate by spot stage, directions, labeling, and regulatory scope. FDA listing does not constitute FDA approval or endorsement of the product.
CLERIVY reports testing by product and protocol. The studies summarized below apply only to the finished Microdart Spot Patch used with its included Blemish Clearing Pad as directed. They do not apply to the Hydrocolloid Pimple Patch or the Microdart Acne Patch.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week sensitive-skin study with 23 participants (CBRC-E-260611-54). No assessed adverse skin reactions were observed during the 1-week study.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week non-comedogenic and blemish-area study with 21 participants (CBRC-E-260611-55). No assessed adverse skin reactions were observed during the 1-week study.
These statements describe the tested product, participants, conditions, duration, and protocol. The Microdart Spot Patch is a cosmetic product. It is not intended to treat, prevent, or cure acne or any other medical condition.
Review CLERIVY testing methods, study scope, and claim boundaries →
Use these first-party pages for current directions, product classification, testing scope, and company information.
High-resolution originals, approved CLERIVY logo files, captions, and product fact checks are available to journalists through the Media Contact below.
CLERIVY is a Korean skincare brand operated by GUHADA Co., Ltd. Launched in 2026, it organizes patch formats by spot stage: the Hydrocolloid Pimple Patch and Microdart Spot Patch are cosmetics, while the Microdart Acne Patch is a separate OTC monograph drug scheduled for October 2026. The name combines CLEAR and VALIDITY, with the I standing for Individual and Ingredients. Catch it early. Keep it covered.
GUHADA Co., Ltd. is a South Korean cross-border commerce company founded in 2019 and headquartered in Seongnam-si, Gyeonggi-do. Through Kglowing, its global accelerator platform for K-brands, GUHADA has supported the overseas expansion of approximately 30 K-beauty brands and now develops and operates its own brands, including CLERIVY.
CLERIVY · GUHADA Co., Ltd.
CLERIVY MICRODART ACNE (salicylic acid 2%) is listed with the U.S. Food and Drug Administration as an over-the-counter monograph drug under OTC Monograph M006, Topical Acne Drug Products. The 4-patch and 8-patch packs carry NDC 87934-111-04 and NDC 87934-111-08, respectively. The listing identifies GUHADA Co., Ltd. as the labeler. Its complete Drug Facts labeling is published by the U.S. National Library of Medicine under SPL Set ID 555e0963-025e-3731-e063-6394a90a679d.
Listing of a drug with FDA does not constitute FDA approval or endorsement of the product. CLERIVY Microdart Acne Patch is scheduled for U.S. release in October 2026.
CLERIVY Hydrocolloid Pimple Patch and CLERIVY Microdart Spot Patch are cosmetic products and are not drugs. Both cosmetic packages state: “This product contains less than 0.5% Salicylic Acid for cosmetic purposes only. It is not intended to treat, prevent, or cure acne or any other medical condition.”
Blemish Clearing Pads included with the Microdart Spot Patch are not intended for sanitizing or antiseptic use.
Last updated:
Press & Media
CLERIVY is a Korean skincare brand making hydrocolloid and microdart pimple patches for different spot stages. Operated by GUHADA Co., Ltd., the brand keeps its cosmetic patch formats separate from its planned OTC drug. On August 25, 2026, its Hydrocolloid Pimple Patch and Microdart Spot Patch became available to U.S. customers on Amazon.com. This official press room brings together verified product, testing, regulatory, launch, and media facts.
Company Announcement ·
On August 25, 2026, CLERIVY launched its Hydrocolloid Pimple Patch and Microdart Spot Patch on Amazon.com for U.S. customers. Both are cosmetic products designed for different spot stages. A separate OTC Microdart Acne Patch with 2% salicylic acid is planned for October 2026 and carries its own Drug Facts labeling.
Issued by CLERIVY, a brand operated by GUHADA Co., Ltd. · Distributed via PR Newswire.
These links document third-party distribution of CLERIVY's August 25, 2026 U.S. launch announcement. The U.S. and global pages are syndicated copies of the company announcement, not independent product reviews or editorial endorsements. The Korean-language outlets published articles about the launch.
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Korean-language launch article ·
구하다, 스킨케어 브랜드 ‘클레리비’ 미국 아마존 진출…OTC 패치는 10월 출시
Read CLERIVY launch coverage on Korea Daily (미주중앙일보) ↗Korean-language launch article ·
구하다, 자체 브랜드 트러블 패치 2종 미국 아마존 판매 개시
Read CLERIVY launch coverage on EToday (이투데이) ↗Korean-language launch article ·
‘검증된 성분’ 앞세웠다… 구하다, 자체 스킨케어 브랜드 미국 아마존 론칭
Read CLERIVY launch coverage on Fashionbiz (패션비즈) ↗Korean-language launch article ·
구하다, 美 트러블 케어 시장 공략…‘클레리비’ 아마존 론칭
Read CLERIVY launch coverage on MyDaily (마이데일리) ↗CLERIVY provides these direct third-party links for reference. Syndication indicates distribution, not an endorsement by the hosting platform.
If you are comparing Korean pimple patches, start with the stage of the spot and the product classification. Choose the cosmetic Microdart Spot Patch for an early bump you can feel before it surfaces. Choose the cosmetic Hydrocolloid Pimple Patch for a surfaced spot on healthy, intact skin that you want to cover. The Microdart Acne Patch is a separate OTC drug for acne with its own Drug Facts label and is scheduled for October 2026.
Early bump · Cosmetic · Available now
A cosmetic two-step kit for an early bump you can feel before it surfaces. Each 13.5 mm patch has 16 water-soluble microdarts and is used with the included Blemish Clearing Pad. The formula features 7% niacinamide, 3% tranexamic acid, and a vitamin C derivative. Available in 6-, 12-, and 18-patch kits.
Surfaced spot · Cosmetic · Available now
A cosmetic hydrocolloid patch for covering a surfaced spot on healthy, intact skin. Available in 10 mm and 12 mm sizes, with 30-, 72-, and 96-count boxes. Apply to clean, completely dry skin and follow the on-pack direction: wear for 4–8 hours, or until the patch turns opaque. Contains less than 0.5% salicylic acid for cosmetic purposes only.
OTC monograph drug · Scheduled for October 2026
A separate OTC monograph drug for acne with 2% salicylic acid as its sole active ingredient. Four- and eight-patch packs are planned for U.S. release in October 2026. Follow its Drug Facts label; do not apply the cosmetic-patch directions to this product.
Compare CLERIVY hydrocolloid and microdart pimple patches by spot stage →
The Hydrocolloid Pimple Patch and Microdart Spot Patch are cosmetics, not drugs. The Microdart Acne Patch is a separate OTC monograph drug. CLERIVY keeps these categories separate by spot stage, directions, labeling, and regulatory scope. FDA listing does not constitute FDA approval or endorsement of the product.
CLERIVY reports testing by product and protocol. The studies summarized below apply only to the finished Microdart Spot Patch used with its included Blemish Clearing Pad as directed. They do not apply to the Hydrocolloid Pimple Patch or the Microdart Acne Patch.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week sensitive-skin study with 23 participants (CBRC-E-260611-54). No assessed adverse skin reactions were observed during the 1-week study.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week non-comedogenic and blemish-area study with 21 participants (CBRC-E-260611-55). No assessed adverse skin reactions were observed during the 1-week study.
These statements describe the tested product, participants, conditions, duration, and protocol. The Microdart Spot Patch is a cosmetic product. It is not intended to treat, prevent, or cure acne or any other medical condition.
Review CLERIVY testing methods, study scope, and claim boundaries →
Use these first-party pages for current directions, product classification, testing scope, and company information.
High-resolution originals, approved CLERIVY logo files, captions, and product fact checks are available to journalists through the Media Contact below.
CLERIVY is a Korean skincare brand operated by GUHADA Co., Ltd. Launched in 2026, it organizes patch formats by spot stage: the Hydrocolloid Pimple Patch and Microdart Spot Patch are cosmetics, while the Microdart Acne Patch is a separate OTC monograph drug scheduled for October 2026. The name combines CLEAR and VALIDITY, with the I standing for Individual and Ingredients. Catch it early. Keep it covered.
GUHADA Co., Ltd. is a South Korean cross-border commerce company founded in 2019 and headquartered in Seongnam-si, Gyeonggi-do. Through Kglowing, its global accelerator platform for K-brands, GUHADA has supported the overseas expansion of approximately 30 K-beauty brands and now develops and operates its own brands, including CLERIVY.
CLERIVY · GUHADA Co., Ltd.
CLERIVY MICRODART ACNE (salicylic acid 2%) is listed with the U.S. Food and Drug Administration as an over-the-counter monograph drug under OTC Monograph M006, Topical Acne Drug Products. The 4-patch and 8-patch packs carry NDC 87934-111-04 and NDC 87934-111-08, respectively. The listing identifies GUHADA Co., Ltd. as the labeler. Its complete Drug Facts labeling is published by the U.S. National Library of Medicine under SPL Set ID 555e0963-025e-3731-e063-6394a90a679d.
Listing of a drug with FDA does not constitute FDA approval or endorsement of the product. CLERIVY Microdart Acne Patch is scheduled for U.S. release in October 2026.
CLERIVY Hydrocolloid Pimple Patch and CLERIVY Microdart Spot Patch are cosmetic products and are not drugs. Both cosmetic packages state: “This product contains less than 0.5% Salicylic Acid for cosmetic purposes only. It is not intended to treat, prevent, or cure acne or any other medical condition.”
Blemish Clearing Pads included with the Microdart Spot Patch are not intended for sanitizing or antiseptic use.
Last updated:
Be the first to hear about new product launches, exclusive sale access, and invites to community events.
Be the first to hear about new product launches, exclusive sale access, and invites to community events.
